Influence of the gynecologic oncologist on the survival of ovarian cancer patients

John K. Chan, Daniel S. Kapp, Jacob Y. Shin, Amreen Husain, Nelson N. Teng, Jonathan S. Berek, Kathryn Osann, Gary S Leiserowitz, Rosemary D Cress, Cynthia O'Malley

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

OBJECTIVE: To estimate the influence of gynecologic oncologists on the treatment and outcome of patients with ovarian cancer. METHODS: Data were obtained from California Cancer Registry from 1994 to 1996. Kaplan-Meier and Cox proportional hazard methods were used for analyses. RESULTS: Of 1,491 patients, the median age was 65 years (range: 13-100). Only 34.1% received care by gynecologic oncologists (group A) while 65.9% were treated by others (group B). Women in group A were more affluent (P<.001), were more educated (P=.036), were classified as white-collar employees (P=.128), and lived in urban regions (P<.001) compared with group B. Patients who saw gynecologic oncologists were more likely to have surgery as their initial treatment (91.9% versus 69.1%; P<.001), present with advanced (stage III-IV) cancers (78.2% versus 70.5%; P<.001), have more grade 3 tumors (61.7% versus 39.9%; P=.048), and receive chemotherapy (90.0% versus 70.1%; P<.001). Women in group B had a fourfold higher risk of having unstaged cancers (8.0% versus 2.1%; P<.001). The 5-year disease-specific survival of group A patients was 38.6% compared with 30.3% in group B (P<.001). On multivariable analysis, early stage, lower grade, and treatment by gynecologic oncologists were independent prognostic factors for improved survival. After adjusting for surgery and chemotherapy, there was no improvement in survival associated with care by gynecologic oncologists (hazard ratio=0.90, 95% confidence interval 0.78-1.03; P=.133). CONCLUSION: In this study of 1,491 women, those who were treated by gynecologic oncologists were more likely to undergo primary staging surgery and receive chemotherapy. Stage, grade of disease, and treatment by gynecologic oncologists were important prognosticators.

Original languageEnglish (US)
Pages (from-to)1342-1350
Number of pages9
JournalObstetrics and Gynecology
Volume109
Issue number6
DOIs
StatePublished - Jun 2007

Fingerprint

Ovarian Neoplasms
Survival
Drug Therapy
Neoplasms
Female Genital Diseases
Oncologists
Registries
Therapeutics
Confidence Intervals

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Chan, J. K., Kapp, D. S., Shin, J. Y., Husain, A., Teng, N. N., Berek, J. S., ... O'Malley, C. (2007). Influence of the gynecologic oncologist on the survival of ovarian cancer patients. Obstetrics and Gynecology, 109(6), 1342-1350. https://doi.org/10.1097/01.AOG.0000265207.27755.28

Influence of the gynecologic oncologist on the survival of ovarian cancer patients. / Chan, John K.; Kapp, Daniel S.; Shin, Jacob Y.; Husain, Amreen; Teng, Nelson N.; Berek, Jonathan S.; Osann, Kathryn; Leiserowitz, Gary S; Cress, Rosemary D; O'Malley, Cynthia.

In: Obstetrics and Gynecology, Vol. 109, No. 6, 06.2007, p. 1342-1350.

Research output: Contribution to journalArticle

Chan, JK, Kapp, DS, Shin, JY, Husain, A, Teng, NN, Berek, JS, Osann, K, Leiserowitz, GS, Cress, RD & O'Malley, C 2007, 'Influence of the gynecologic oncologist on the survival of ovarian cancer patients', Obstetrics and Gynecology, vol. 109, no. 6, pp. 1342-1350. https://doi.org/10.1097/01.AOG.0000265207.27755.28
Chan, John K. ; Kapp, Daniel S. ; Shin, Jacob Y. ; Husain, Amreen ; Teng, Nelson N. ; Berek, Jonathan S. ; Osann, Kathryn ; Leiserowitz, Gary S ; Cress, Rosemary D ; O'Malley, Cynthia. / Influence of the gynecologic oncologist on the survival of ovarian cancer patients. In: Obstetrics and Gynecology. 2007 ; Vol. 109, No. 6. pp. 1342-1350.
@article{61baef2a30544cbfb79f094bf6389562,
title = "Influence of the gynecologic oncologist on the survival of ovarian cancer patients",
abstract = "OBJECTIVE: To estimate the influence of gynecologic oncologists on the treatment and outcome of patients with ovarian cancer. METHODS: Data were obtained from California Cancer Registry from 1994 to 1996. Kaplan-Meier and Cox proportional hazard methods were used for analyses. RESULTS: Of 1,491 patients, the median age was 65 years (range: 13-100). Only 34.1{\%} received care by gynecologic oncologists (group A) while 65.9{\%} were treated by others (group B). Women in group A were more affluent (P<.001), were more educated (P=.036), were classified as white-collar employees (P=.128), and lived in urban regions (P<.001) compared with group B. Patients who saw gynecologic oncologists were more likely to have surgery as their initial treatment (91.9{\%} versus 69.1{\%}; P<.001), present with advanced (stage III-IV) cancers (78.2{\%} versus 70.5{\%}; P<.001), have more grade 3 tumors (61.7{\%} versus 39.9{\%}; P=.048), and receive chemotherapy (90.0{\%} versus 70.1{\%}; P<.001). Women in group B had a fourfold higher risk of having unstaged cancers (8.0{\%} versus 2.1{\%}; P<.001). The 5-year disease-specific survival of group A patients was 38.6{\%} compared with 30.3{\%} in group B (P<.001). On multivariable analysis, early stage, lower grade, and treatment by gynecologic oncologists were independent prognostic factors for improved survival. After adjusting for surgery and chemotherapy, there was no improvement in survival associated with care by gynecologic oncologists (hazard ratio=0.90, 95{\%} confidence interval 0.78-1.03; P=.133). CONCLUSION: In this study of 1,491 women, those who were treated by gynecologic oncologists were more likely to undergo primary staging surgery and receive chemotherapy. Stage, grade of disease, and treatment by gynecologic oncologists were important prognosticators.",
author = "Chan, {John K.} and Kapp, {Daniel S.} and Shin, {Jacob Y.} and Amreen Husain and Teng, {Nelson N.} and Berek, {Jonathan S.} and Kathryn Osann and Leiserowitz, {Gary S} and Cress, {Rosemary D} and Cynthia O'Malley",
year = "2007",
month = "6",
doi = "10.1097/01.AOG.0000265207.27755.28",
language = "English (US)",
volume = "109",
pages = "1342--1350",
journal = "Obstetrics and Gynecology",
issn = "0029-7844",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Influence of the gynecologic oncologist on the survival of ovarian cancer patients

AU - Chan, John K.

AU - Kapp, Daniel S.

AU - Shin, Jacob Y.

AU - Husain, Amreen

AU - Teng, Nelson N.

AU - Berek, Jonathan S.

AU - Osann, Kathryn

AU - Leiserowitz, Gary S

AU - Cress, Rosemary D

AU - O'Malley, Cynthia

PY - 2007/6

Y1 - 2007/6

N2 - OBJECTIVE: To estimate the influence of gynecologic oncologists on the treatment and outcome of patients with ovarian cancer. METHODS: Data were obtained from California Cancer Registry from 1994 to 1996. Kaplan-Meier and Cox proportional hazard methods were used for analyses. RESULTS: Of 1,491 patients, the median age was 65 years (range: 13-100). Only 34.1% received care by gynecologic oncologists (group A) while 65.9% were treated by others (group B). Women in group A were more affluent (P<.001), were more educated (P=.036), were classified as white-collar employees (P=.128), and lived in urban regions (P<.001) compared with group B. Patients who saw gynecologic oncologists were more likely to have surgery as their initial treatment (91.9% versus 69.1%; P<.001), present with advanced (stage III-IV) cancers (78.2% versus 70.5%; P<.001), have more grade 3 tumors (61.7% versus 39.9%; P=.048), and receive chemotherapy (90.0% versus 70.1%; P<.001). Women in group B had a fourfold higher risk of having unstaged cancers (8.0% versus 2.1%; P<.001). The 5-year disease-specific survival of group A patients was 38.6% compared with 30.3% in group B (P<.001). On multivariable analysis, early stage, lower grade, and treatment by gynecologic oncologists were independent prognostic factors for improved survival. After adjusting for surgery and chemotherapy, there was no improvement in survival associated with care by gynecologic oncologists (hazard ratio=0.90, 95% confidence interval 0.78-1.03; P=.133). CONCLUSION: In this study of 1,491 women, those who were treated by gynecologic oncologists were more likely to undergo primary staging surgery and receive chemotherapy. Stage, grade of disease, and treatment by gynecologic oncologists were important prognosticators.

AB - OBJECTIVE: To estimate the influence of gynecologic oncologists on the treatment and outcome of patients with ovarian cancer. METHODS: Data were obtained from California Cancer Registry from 1994 to 1996. Kaplan-Meier and Cox proportional hazard methods were used for analyses. RESULTS: Of 1,491 patients, the median age was 65 years (range: 13-100). Only 34.1% received care by gynecologic oncologists (group A) while 65.9% were treated by others (group B). Women in group A were more affluent (P<.001), were more educated (P=.036), were classified as white-collar employees (P=.128), and lived in urban regions (P<.001) compared with group B. Patients who saw gynecologic oncologists were more likely to have surgery as their initial treatment (91.9% versus 69.1%; P<.001), present with advanced (stage III-IV) cancers (78.2% versus 70.5%; P<.001), have more grade 3 tumors (61.7% versus 39.9%; P=.048), and receive chemotherapy (90.0% versus 70.1%; P<.001). Women in group B had a fourfold higher risk of having unstaged cancers (8.0% versus 2.1%; P<.001). The 5-year disease-specific survival of group A patients was 38.6% compared with 30.3% in group B (P<.001). On multivariable analysis, early stage, lower grade, and treatment by gynecologic oncologists were independent prognostic factors for improved survival. After adjusting for surgery and chemotherapy, there was no improvement in survival associated with care by gynecologic oncologists (hazard ratio=0.90, 95% confidence interval 0.78-1.03; P=.133). CONCLUSION: In this study of 1,491 women, those who were treated by gynecologic oncologists were more likely to undergo primary staging surgery and receive chemotherapy. Stage, grade of disease, and treatment by gynecologic oncologists were important prognosticators.

UR - http://www.scopus.com/inward/record.url?scp=34249912383&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249912383&partnerID=8YFLogxK

U2 - 10.1097/01.AOG.0000265207.27755.28

DO - 10.1097/01.AOG.0000265207.27755.28

M3 - Article

VL - 109

SP - 1342

EP - 1350

JO - Obstetrics and Gynecology

JF - Obstetrics and Gynecology

SN - 0029-7844

IS - 6

ER -